Fentanyl (Instanyl®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000390
English
Authors' recommendations:
Fentanyl intranasal spray (Instanyl®) is recommended as an option for use within NHS Wales for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain.
Fentanyl intranasal spray (Instanyl®) should only be considered as an option for the management of breakthrough cancer pain when immediate release oral opioids (e.g. morphine, oxycodone) are either inadequate or unsuitable.
Fentanyl intranasal spray (Instanyl®) may be suitable for shared care but should be initiated by, and remain under the supervision of, a physician experienced in the management of opioid therapy in cancer patients.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=158208&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Fentanyl
- Administration, Intranasal
- Pain
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.